Company: DVAX
Filing Date: 2025-04-15
Form Type: PRER14A
Source: 0000930413-25-001254
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-15
Form: PRER14A
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14AINFORMATION

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

(Amendment No. 1)</div>

| Filed by the Registrant ☒ | Filed by a Party other than the Registrant ☐ |

Check the appropriate box:

| ☒ | Preliminary Proxy Statement                                                     |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement                                                      |
| ☐ | Definitive Additional Materials                                                 |
| ☐ | Soliciting Material under §240.14a-12                                           |

<div align='center'>(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</div>

Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required.                                                                                     |
| ☐ | Fee paid previously with preliminary materials.                                                      |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. |

<div align='center'>PRELIMINARY PROXY STATEMENT—SUBJECT TO COMPLETION DATED APRIL 15, 2025

MESSAGE TO OUR STOCKHOLDERS</div>

April [ ], 2025

Dear Fellow Stockholders:

On behalf of the Board of Directors (the “Board”) of Dynavax
Technologies Corporation (“Dynavax” or the “Company”), we are pleased to invite you to attend the 2025 Annual
Meeting of Stockholders of Dynavax. More details on the Annual Meeting can be found in the enclosed notice and proxy materials.

Executing on our strategic plan to drive long-term stockholder value

In 2024, we successfully executed across our strategic priorities and delivered
on our commitments to our stockholders. Thanks to the hard work and dedication of our Dynavax team members we achieved record HEPLISAV-B®
product revenue of $268.4 million in 2024, a 26% increase from 2023, adjusted EBITDA(excluding stock-based compensation)
of $51.9 million, a 329% increase from 2023, advanced our pipeline programs, achieved profitability